Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
about
The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer developmentEpigenetic regulation in human melanoma: past and futureA DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effectEmbryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stabilityDisulfiram suppresses growth of the malignant pleural mesothelioma cells in part by inducing apoptosisEH3 (ABHD9): the first member of a new epoxide hydrolase family with high activity for fatty acid epoxides.Proteome analysis of human gastric cardia adenocarcinoma by laser capture microdissection.The characterization of DNA methylation-mediated regulation of bovine placental lactogen and bovine prolactin-related protein-1 genesIdentification of epigenetically regulated genes that predict patient outcome in neuroblastomaEpigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesThe identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancerLeft ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy.Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1.Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.Aberrant DNA methylation in malignant melanomaRNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin.Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.p53-Inducible DHRS3 is an endoplasmic reticulum protein associated with lipid droplet accumulation.Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors.DNA methylation subgroups in melanoma are associated with proliferative and immunological processesHOX transcription factors are potential targets and markers in malignant mesotheliomaHigh-throughput methylation profiling by MCA coupled to CpG island microarrayPharmacological unmasking microarray approach-based discovery of novel DNA methylation markers for hepatocellular carcinoma.HOXD13 methylation status is a prognostic indicator in breast cancer.Generation and characterization of epoxide hydrolase 3 (EPHX3)-deficient miceGenome-wide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profileMammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism.REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.Homeobox gene expression profile indicates HOXA5 as a candidate prognostic marker in oral squamous cell carcinoma.Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors.Growth factors and oncogenes as targets in melanoma: lost in translation?The impact of genomics in understanding human melanoma progression and metastasis.Isolation and bioinformatics analysis of differentially methylated genomic fragments in human gastric cancer.Deregulated Aurora-B induced tetraploidy promotes tumorigenesis.Genome-wide screen of promoter methylation identifies novel markers in melanoma.Epigenetics in human melanoma.FBLN4 as candidate gene associated with long-term and short-term survival with primary glioblastoma.The effect of alendronate on proteome of hepatocellular carcinoma cell lines.
P2860
Q28084488-915E115E-B74A-4269-AFFB-C726A37C218DQ28085681-5BC08492-DDDF-4F9C-9264-AE518904FBF2Q28237387-9E5765AF-1A36-4EF3-8646-3DEF0DC31DAFQ28508931-C8DB40C9-FD84-43DB-94E8-72747ADFCF35Q28541751-424B8465-3A13-4DFE-94BA-4F598156CC18Q33288850-34F3E63E-8326-4063-AF6C-E72A924D8C34Q33302217-993ADDBC-65BA-4B9D-A7FF-5918169553F6Q33414882-80065A27-881F-43CB-9B9F-3050A713CA3CQ33818726-F6672AE4-7E6C-4639-B26E-9CB94B697CC2Q33980682-83B005A0-96B4-47D6-9BA8-2059492DE02AQ34050388-29C03732-E8BF-4016-9CF6-DBC72147C1B4Q34124934-5060D6DD-E603-4431-8480-F0A782DF03BCQ34181789-698A2500-5D7F-4A60-A3B9-99D94D498240Q34356422-3D896A2F-DCD5-4958-922D-727B5C493EB6Q34452297-A26D5087-6F42-4081-99A9-705254497593Q34516587-57905ECF-9078-44CF-94AE-2BBD5CCEEFD1Q34558896-1005531F-7BEC-4E09-97B6-D16F28161235Q34755642-22E2A512-951C-4371-9910-3E3EABB5AB66Q34989150-705FEDE1-9047-405D-A7D1-A14B079DB07BQ35150180-88E7E429-6DBF-4AFE-9F41-5E1969E46FB6Q35689954-EEA03608-6893-4137-90B3-15C486B18674Q35834765-461B1DAD-5CB5-4605-B2BD-AF2FDF89A36FQ35921127-CAB2FD46-A0AB-4B2B-8277-815E03F3704FQ36004673-7E2495A2-C81D-46D2-989E-AE6309F8FC77Q36014433-B6B11A1C-40F6-4729-8E6F-62AB5771C84DQ36261511-2A09DE70-5EDE-41B2-BA89-2C959A4D31F8Q36338641-8CB39A8C-4BC6-4C64-90AF-CD5CDC3FC8B8Q36477174-E14B0191-65DE-4996-90B7-B28E0ADF8F30Q36612260-D9F64163-E401-4C63-8FDE-2B3FD566A320Q36629559-E8EBD7AB-610C-4B12-8420-9990AFDC377FQ36645669-7834D2F5-4819-49FD-A518-5EB9AC4CC425Q37004685-3AA00384-0092-4F6D-BF4E-3A6285BF8F3BQ37045217-87F0865B-D683-4D88-9817-2995AB884057Q37205801-D49E7090-F96A-4AE2-8FB0-31D179031CFCQ37220638-7EC16BBE-4FA4-47F3-B28E-6A566C95AF26Q37280830-CFDA763B-B051-4D22-A899-ABE13DAC8763Q37287368-82B7AC5F-B108-469A-87FC-80C4656A7504Q37531849-127EC0B2-5019-4437-8E4E-3FCCE95B9EAFQ37596139-26BB492D-44E6-4C41-B6B0-C3ED2FC7DD87Q37599483-2A639F8C-7B02-4923-8851-E0046DC66FBF
P2860
Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@ast
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@en
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@nl
type
label
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@ast
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@en
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@nl
prefLabel
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@ast
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@en
Silencing of Peroxiredoxin 2 a ...... in human malignant melanomas.
@nl
P2093
P1433
P1476
Silencing of Peroxiredoxin 2 a ...... s in human malignant melanomas
@en
P2093
Fujio Otsuka
Junichi Furuta
Kanako Kikuchi
Yoshihiro Umebayashi
Yoshimasa Nobeyama
P304
P356
10.1158/0008-5472.CAN-06-0157
P407
P577
2006-06-01T00:00:00Z